BrainsWay

BrainsWay is a Jerusalem-based neurotechnology company specializing in non-invasive brain stimulation through its proprietary Deep Transcranial Magnetic Stimulation (dTMS) platform. At the core of their technology is the patented H-Coil, which generates magnetic fields capable of reaching deeper and broader neural structures than conventional figure-eight TMS coils, enabling more targeted modulation of brain circuits implicated in psychiatric and neurological disorders. Their FDA-cleared BrainsWay Deep TMS System is deployed in psychiatric clinics, hospitals, and treatment centers across more than 60 countries, offering patients a non-pharmacological alternative for conditions that have historically been difficult to treat. The platform is designed for clinical scalability, with a single device capable of supporting multiple treatment indications through interchangeable coil configurations.

BrainsWay has secured FDA clearances for three major indications: major depressive disorder, obsessive-compulsive disorder, and smoking cessation, establishing it as one of the few neuromodulation companies with a diversified regulatory portfolio in psychiatry. The company is publicly traded on NASDAQ under the ticker BWAY, providing it with capital market access to fund ongoing clinical research and commercial expansion. Their clinical evidence base spans thousands of patients across multiple controlled trials, lending scientific credibility to their efficacy and safety claims in highly scrutinized therapeutic areas. BrainsWay continues to advance its pipeline with investigational programs targeting additional conditions such as PTSD, bipolar disorder, and addiction, broadening its potential addressable market considerably.

BrainsWay occupies a strategically important position in the neurotech industry as a bridge between neuroscience research and scalable clinical application in mental health. At a time when the global psychiatric treatment landscape faces a significant unmet need and growing interest in non-drug interventions, their technology offers a compelling alternative to pharmacotherapy for patients who have failed conventional treatments. Their success in obtaining multiple FDA clearances for psychiatric indications demonstrates that neuromodulation can move beyond single-use applications and evolve into a versatile therapeutic platform. For the broader neurotech field, BrainsWay represents a proof of concept that deep, non-invasive brain stimulation can be commercialized responsibly, regulatory rigor and clinical validation intact, setting a meaningful benchmark for companies developing the next generation of brain-based therapies.